{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:42:20Z","timestamp":1791308540847,"version":"4.3.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T00:00:00Z","timestamp":1739664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcf.2025.02.010","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:55:09Z","timestamp":1740153309000},"page":"290-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Strategies used to access CFTR modulators in countries without reimbursement agreements"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-1076","authenticated-orcid":false,"given":"Jonathan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0973-3194","authenticated-orcid":false,"given":"Grace","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.02.010_bib0001","unstructured":"Cystic Fibrosis Facts and Figures | Vertex Pharmaceuticals n.d. https:\/\/www.vrtx.com\/medicines\/cystic-fibrosis-facts-and-figures\/(accessed September 23, 2024)."},{"key":"10.1016\/j.jcf.2025.02.010_bib0002","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.02.010_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.02.010_bib0004","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/cpt.3214","article-title":"Pharmacokinetic enhancement of elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis: a cost reduction strategy to address global disparities in access","volume":"115","author":"Hong","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcf.2025.02.010_bib0005","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S2055-6640(20)30324-1","article-title":"High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C","volume":"3","author":"Hill","year":"2017","journal-title":"J Virus Erad"},{"key":"10.1016\/j.jcf.2025.02.010_bib0006","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1080\/17441692.2021.1959940","article-title":"Mapping buyer's clubs; what role do they play in achieving equitable access to medicines?","volume":"17","author":"Rhodes","year":"2022","journal-title":"Glob Public Health"},{"key":"10.1016\/j.jcf.2025.02.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","author":"Guo","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.02.010_bib0008","unstructured":"Supreme Court ordered the National Health Fund and the Ministry of Health to take the necessary steps to acquire and supply the drug identified as Trikafta - DOE | Legal News n.d. https:\/\/actualidadjuridica.doe.cl\/corte-suprema-ordeno-a-fondo-nacional-de-salud-y-el-ministerio-de-salud-realizar-las-gestiones-pertinentes-para-la-adquisicion-y-suministro-del-farmaco-identificado-como-trikafta\/(accessed November 5, 2024)."},{"key":"10.1016\/j.jcf.2025.02.010_bib0009","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jcf.2024.05.006","article-title":"Impact of interruption of CFTR modulator therapies","volume":"23","author":"Capraz Yavuz","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.02.010_bib0010","unstructured":"Mandatory license for high-priced medicines | MIEM 2024. https:\/\/www.gub.uy\/ministerio-industria-energia-mineria\/comunicacion\/noticias\/licencia-obligatoria-para-medicamento-alto-precio (accessed October 30, 2024)."},{"issue":"5","key":"10.1016\/j.jcf.2025.02.010_bib23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.02.010_bib0011","unstructured":"Law 27552 Honorable Congress of the Argentine Nation| Argentina.gob.ar 2020. https:\/\/www.argentina.gob.ar\/normativa\/nacional\/ley-27552-340915\/normas-modifican (accessed October 30, 2024)."},{"key":"10.1016\/j.jcf.2025.02.010_bib0012","series-title":"Agreement on trade-related aspects of intellectual property rights (unamended)","year":"1994"},{"key":"10.1016\/j.jcf.2025.02.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.02.002","article-title":"Real-world outcomes of generic elexacaftor\/tezacaftor\/ivacaftor (gETI) in South Africans (SA) with CF using standard versus clarithromycin-boosted gETI, modulator-sparing strategies to reduce cost","author":"Zampoli","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.02.010_bib0014","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jcf.2014.03.009","article-title":"European cystic fibrosis society standards of care: framework for the Cystic Fibrosis Centre","volume":"13","author":"Conway","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.02.010_bib0015","unstructured":"SACFA and its affiliated doctors announcement on Trikafta - SACFA n.d. https:\/\/sacfa.org.za\/2024-trikaftanews\/ (accessed May 31, 2024)."},{"key":"10.1016\/j.jcf.2025.02.010_bib0016","unstructured":"We demand access for all - SACFA 2024. https:\/\/sacfa.org.za\/equal-access-for-cf-patients\/(accessed January 15, 2025)."},{"key":"10.1016\/j.jcf.2025.02.010_bib0017","unstructured":"Global Health Expenditure Database n.d. https:\/\/apps.who.int\/nha\/database (accessed November 23, 2024)."},{"issue":"10","key":"10.1016\/j.jcf.2025.02.010_bib22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2213-2600(23)00297-7","article-title":"Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.02.010_bib0018","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12916-018-1162-z","article-title":"Pathways to ensure universal and affordable access to hepatitis C treatment","volume":"16","author":"Douglass","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.jcf.2025.02.010_bib0019","article-title":"Threat of compulsory licences could increase access to essential medicines","volume":"365","author":"Ooms","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jcf.2025.02.010_bib0020","unstructured":"Nolen S., Robbins R. This cystic fibrosis drug is a \u2018miracle\u2019 but these families can't get it - the New York times. New York Times 2023."},{"key":"10.1016\/j.jcf.2025.02.010_bib0021","unstructured":"Health and Social Care Select Committee. Written evidence submitted to the \u201cAvailability of Orkambi on the NHS inquiry.\u201d 2019."}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000578?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000578?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:36:30Z","timestamp":1777332990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1569199325000578"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.02.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies used to access CFTR modulators in countries without reimbursement agreements","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}